Hematology & Medical Oncology
1998
M.D., Seoul National University College Of Medicine
2004
M.S., Seoul National University Graduate School (Internal medicine)
2007
Ph.D., Seoul National University Graduate School (Molecular oncology)
Experience
2012 – 2013
Visiting Professor, Department of Systems Biology MD Anderson Cancer Center
2013 – 2018
Associate Professor, Department of Internal Medicine (Division of Hematology-Oncology) Seoul National University College of Medicine / Seoul National University Bundang Hospital
2016 – 2020
Chief, Division of Hematology-Oncology Seoul National University Bundang Hospital
2024 –
Chief Director of Comprehensive Cancer Center, Seoul National University Bundang Hospital
·
Member (Domestic) – Korean Society of Medical Oncology (KSMO), Korean Cancer Association (KCA), Korean Cancer Study
·
Group (KCSG), Korean Society of Thrombosis and Hemostasis (KSTH), Korean Association of Internal Medicine (KAIM)
·
- Member (International) – American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), American Association of Cancer Research (AACR)
·
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lam, L. L., Pavlakis, N., Shitara, K., Sjoquist, K. M., Martin, A. J., Yip, S., Kang, Y. K., Bang, Y. J., Chen, L. T., Moehler, M., Bekaii-Saab, T., Alcindor, T., O’Callaghan, C. J., Tebbutt, N. C., Hague, W., Chan, H., Rha, S. Y., Lee, K. W., Gebski, V., Jaworski, A., & 4 others, Dec 2023,
In: BMC Cancer. 23, 1, 180.
·
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas
Lee, J., Park, S., Jung, H. A., Lee, S. H., Seo, S., Kim, S. B., Kim, J. W., Lee, K. W., Kang, E. J., Kim, J. W., Choi, Y. J., Shim, B. Y., An, H. J., Park, L. C., Shin, S. H., Kim, J. J., Oh, S. Y., Kim, M. K. & Ahn, M. J., 1 Oct 2023,
In: Cancer. 129, 19, p. 2966-2974 9 p.
·
Correction: Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years (Gastric Cancer, (2020), 23, 6, (1051-1063), 10.1007/s10120-020-01076-2)
Choi, Y., Kim, N., Yun, C. Y., Choi, Y. J., Yoon, H., Shin, C. M., Park, Y. S., Ahn, S. H., Joong Park, D., Lee, H. S., Kim, J. W., Kim, J. W., Lee, K. W., Chang, W., Park, J. H., Lee, Y. J., Lee, K. H., Kim, Y. H., Lee, D. H. & Kim, H. H., Sep 2023,
In: Gastric Cancer. 26, 5, p. 843-845 3 p.
